Gan & Lee Pharmaceuticals Co Ltd (603087) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Gan & Lee Pharmaceuticals Co Ltd ¥18.85, price ¥74.56, upside -74.7%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Gan & Lee Pharmaceuticals Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥30.97 – ¥136.10 · fair‑value band ¥17.05 – ¥29.38 · the ¥74.56 price screens above the ¥18.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Gan & Lee Pharmaceuticals Co in your weekly email
Every Wednesday you see whether Gan & Lee Pharmaceuticals Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China.
Show more
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and other medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Stock analysis
Gan & Lee Pharmaceuticals Co Ltd (603087) currently trades at ¥74.56, while our model-based Fair Value estimate is ¥18.85, implying the stock looks roughly 295.6% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥44.34 per share, and 0 of the 17 models we run sit above the ¥74.56 price.
Bear case: the Asset-Based group reads lowest at ¥13.04, and 17 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥17.05 (bear) to ¥29.38 (bull), the price of ¥74.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Gan & Lee Pharmaceuticals Co Ltd reported revenue of 4.1B CNY in FY2025 versus 3.6B CNY in FY2021, a compound +2.9%/yr. Reported net income was 1.1B CNY in FY2025, compounding −5.8%/yr from FY2021.
Key figures
Market cap 44.5B CNY (≈ $6.6B) · P/E ratio 43.1 · P/S ratio 12.2 · EPS (TTM) ¥1.73 · Dividend yield 1.3% · Net margin 28.2% · Return on equity 8.9% · Return on assets (EBIT) 4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −75%, 603087 screens richer than that median.
Fair Value models
Bear ¥17.05Fair Value ¥18.85Bull ¥29.38
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.5340 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+33.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−3.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.0%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3% vs 8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.43% → 20%
2025 sits 134% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Gan & Lee Pharmaceuticals Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−75% · Bottom 25%
Profitability
Return on equity (TTM)9% · Above median
Return on assets4% · Above median
Net margin (TTM)26% · Top 25%
Operating margin (TTM)22% · Top 25%
Growth and dividend
Revenue growth−11% · Bottom 25%
Dividend yield (TTM)1.3% · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)43.1× · Pricier than median
P/B3.83× · Priciest 25%
P/S (TTM)11.29× · Priciest 25%
EV/EBITDA41.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)0· sector 31
PAST (return on equity)35· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)27· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gan & Lee Pharmaceuticals Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/603087
Frequently asked questions
Is Gan & Lee Pharmaceuticals Co Ltd (603087) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥18.85 versus a price of ¥74.56, about −75% upside (overvalued).
What is the fair value of 603087?
Our model-based fair value for Gan & Lee Pharmaceuticals Co Ltd is ¥18.85 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥74.56.
What is the quality score of 603087?
Gan & Lee Pharmaceuticals Co Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gan & Lee Pharmaceuticals Co Ltd (603087)?
Our model-based price target is the fair value of ¥18.85 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ¥17.05, optimistic scenario ¥29.38. It is a calculation from audited fundamentals, not an analyst target.
What is the Gan & Lee Pharmaceuticals Co Ltd stock forecast for 2026?
Our models put fair value at ¥18.85, about −75% upside versus a price of ¥74.56 (overvalued). Cautious scenario ¥17.05, optimistic scenario ¥29.38. The calculation is refreshed regularly with new filings.
What is the revenue of Gan & Lee Pharmaceuticals Co Ltd (603087)?
Gan & Lee Pharmaceuticals Co Ltd reported trailing-twelve-month revenue of about 3.9B CNY (latest available figure, as of Sep 24, 2026).
Does Gan & Lee Pharmaceuticals Co Ltd pay a dividend?
Gan & Lee Pharmaceuticals Co Ltd currently shows a dividend yield of about 1.34% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Gan & Lee Pharmaceuticals Co Ltd (603087)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gan & Lee Pharmaceuticals Co Ltd it is ¥18.85 per share (as of Sep 24, 2026), against a price of ¥74.56. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Gan & Lee Pharmaceuticals Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 603087 trades above its calculated fair value: price ¥74.56, fair value ¥18.85, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603087?
No. The price is what the market pays today (¥74.56); the fair value is what the company's own numbers justify (¥18.85). For Gan & Lee Pharmaceuticals Co Ltd the two are ¥55.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gan & Lee Pharmaceuticals Co Ltd worth?
The market values Gan & Lee Pharmaceuticals Co Ltd at about 44.5B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥74.56; our models calculate a fair value of ¥18.85 per share.
What do the bullish and bearish scenarios say about 603087?
Our models span a range for Gan & Lee Pharmaceuticals Co Ltd: cautious scenario ¥17.05, base ¥18.85, optimistic ¥29.38 per share (as of Sep 24, 2026, price ¥74.56). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603087?
Gan & Lee Pharmaceuticals Co Ltd trades at a price-to-earnings ratio of 43.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥18.85 is built from several models across several years. Other multiples: P/B 3.8, P/S 11.3, EV/EBITDA 41.0.
How solid is the balance sheet of Gan & Lee Pharmaceuticals Co Ltd (603087)?
Balance-sheet figures for Gan & Lee Pharmaceuticals Co Ltd (as of Sep 24, 2026): return on equity 8.9%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 603087 from its 52-week high?
Gan & Lee Pharmaceuticals Co Ltd trades at ¥74.56, about 6% below its 52-week high of ¥79.62 and 43% above the low of ¥52.05 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥18.85 is for.
Which stocks are comparable to Gan & Lee Pharmaceuticals Co Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gan & Lee Pharmaceuticals Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥74.56, calculated fair value ¥18.85 (−75%), Quality Score 61/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603087 calculated?
We run Gan & Lee Pharmaceuticals Co Ltd through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥18.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Gan & Lee Pharmaceuticals Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The closing price on Sep 23, 2026 was ¥74.56. Our model-based fair value is ¥18.85, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gan & Lee Pharmaceuticals Co Ltd right now?
The price sits above even our optimistic bull case (¥29.38). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Gan & Lee Pharmaceuticals Co Ltd (603087) come from?
Earnings per share at Gan & Lee Pharmaceuticals Co Ltd grew +2.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +10.4 %, EBIT margin −8.5 %, tax rate +1.9 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Gan & Lee Pharmaceuticals Co Ltd
How large is the market capitalisation of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The market capitalisation of Gan & Lee Pharmaceuticals Co Ltd is 44.5B CNY (≈ $6.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The price-to-sales ratio of Gan & Lee Pharmaceuticals Co Ltd is 12.2 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gan & Lee Pharmaceuticals Co Ltd (603087)?
Earnings per share at Gan & Lee Pharmaceuticals Co Ltd are ¥1.73 (price ÷ EPS = P/E 43.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The dividend yield of Gan & Lee Pharmaceuticals Co Ltd is 1.3% (payout 57.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The net margin of Gan & Lee Pharmaceuticals Co Ltd is 28.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The return on equity (ROE) of Gan & Lee Pharmaceuticals Co Ltd is 8.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gan & Lee Pharmaceuticals Co Ltd (603087)?
On an EBIT basis the return on assets of Gan & Lee Pharmaceuticals Co Ltd is 4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gan & Lee Pharmaceuticals Co Ltd (603087)?
The operating margin of Gan & Lee Pharmaceuticals Co Ltd is 21.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gan & Lee Pharmaceuticals Co Ltd (603087)?
Revenue at Gan & Lee Pharmaceuticals Co Ltd is growing −10.8% versus a year earlier (3y avg +33.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gan & Lee Pharmaceuticals Co Ltd (603087)?
Earnings per share at Gan & Lee Pharmaceuticals Co Ltd are growing −37.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Gan & Lee Pharmaceuticals Co Ltd (603087) generate?
The free cash flow of Gan & Lee Pharmaceuticals Co Ltd is −142M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Gan & Lee Pharmaceuticals Co Ltd (603087) hold?
Gan & Lee Pharmaceuticals Co Ltd holds more cash than debt, 899M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Gan & Lee Pharmaceuticals Co Ltd in the live analysis
One click puts Gan & Lee Pharmaceuticals Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
